Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OligoG in Cystic Fibrosis with Pseudomonas Aeruginosa
NCT01465529Phase 2Completed
- Sponsor
- AlgiPharma
- Start
- May 2011
- Primary completion
- Oct 2013
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of OligoG in cystic fibrosis (CF) (2 arms), sponsored by AlgiPharma. Primary endpoint: Safety and local tolerability of multiple dose administration of inhaled OligoG at 6 months. Started May 2011; status: completed.
02
Drugs
OligoG
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01465529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01465529.